SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong quarterly results and raised outlook have been overshadowed by a post-earnings selloff, as traders focus on slower contract-booking growth and the stocks premium valuation. Bulls point to strong commercial AI demand and revenue growth, while bears question whether bookings can sustain the growth expectations priced into the shares.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys quarterly results sparked a sharp selloff as traders focused on revenue and GMV misses and moderating growth, despite stronger profit and cash flow; many see the reaction as excessive and point to a rebound, while bears argue the stocks high valuation leaves little room for disappointment.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A record quarterly report and raised fiscal-year outlook, supported by strong bookings and demand for AI-chip testing systems, drove AEHRs sharp rebound. Traders welcomed the results and see further AI-related growth potential, while skeptics question the valuation and whether the move can hold.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigals Q3 results, including strong Rezdiffra growth and its first profitable quarter, are driving attention. Bulls emphasize the launch momentum and MASH market opportunity, while skeptics point to spending and uncertainty around future clinical-outcomes data, debating why the stock faded despite the results.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiservs rally follows a Q3 earnings and revenue beat, a doubled cost-savings target and a planned share buyback, offering relief after a prolonged selloff. Traders are debating whether the results and new management mark a genuine turnaround or merely a bounce, while some attribute the move to short covering.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the following business segments: Cannabis and Plant Propagation. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Organigrams agreement to acquire Aurora, topping Curaleafs competing bid, has driven the sharp rally. Traders are debating whether Curaleaf could counter with a higher offer and whether the deal limits further upside; reactions range from welcoming the acquisition to calling for better terms.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Attention centers on Compass Pathways progress toward completing the FDA application for COMP360, its treatment-resistant depression therapy, and the prospect of an accelerated review and commercial launch in 2027. Traders are hopeful the regulatory milestone will lift the shares, while debating delays, launch execution and competition from Usonas psilocybin application for major depressive disorder.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP is drawing attention as part of the volatile rare-earth and critical-minerals trade, with traders weighing U.S.China supply tensions against the strategic case for domestic production. Some cite MPs magnet deliveries and expansion plans as support, while others focus on the sector-wide selloff and execution risks.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDBs CEO abruptly left for Meta ahead of Investor Day, sparking a sharp selloff and volatile trading. Reaffirmed guidance and former CEO Dev Ittycherias return as interim leader have encouraged dip-buying, while others remain concerned about succession uncertainty and the companys valuation.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins Q3 resultswith stronger operating profitability, expanding margins and record customer reachalongside a new share-repurchase program are driving attention. Bulls welcome the growth and buyback, while skeptics point to weak same-store sales and argue that OTC trading and uncertainty around a relisting are keeping the shares range-bound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology

AstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.

Futures Slide As Tech Tumbles On Fears Of AI Slowdown, Oil Jumps

Futures Slide As Tech Tumbles On Fears Of AI Slowdown, Oil Jumps

 US futures are sliding, dragged by fears of a possible AI development slowdown as well as higher oil prices (Brent > 108), though bond yields are not reacting yet (10Y yield still under 5%). As of 8:00am ET, S&P futures...

Olema Appoints Jason O'Byrne As CFO

(RTTNews) - Olema Pharmaceuticals Inc. (OLMA), a clinical-stage biopharmaceutical company, on Thursday appointed Jason O'Byrne as Chief Financial Officer...

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Pharmaceuticals shares fall after completing OPERA-01 Phase 3 enrollment, with top-line data now expected in Q1 2027.read more...

Lilly’s Phase 3 Breakthrough Ignites Race for the Next Cancer Stock Breakout

Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. $LLY, $NTHI, $COGT, $OLMA, $BMY, $PFE

Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study

Equity

Early ASCO data for OP-3136 pointed to encouraging anti-cancer activity with a clean safety profile, adding momentum to OLMA’s pipeline story.

Olema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on Tuesday

Olema Pharmaceuticals (NASDAQ:OLMA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-olema-pharmaceuticals-inc-stock...

Jennison Associates LLC Takes Position in Olema Pharmaceuticals, Inc. $OLMA

Jennison Associates LLC purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 963,997 shares of the company's stock, valued at approximatel...

Pictet Asset Management Holding SA Trims Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA

Pictet Asset Management Holding SA lessened its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 69.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 502,568...

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Nearly two-thirds of evaluable patients experienced tumor shrinkage, with responses seen across multiple cancer types.</li><li>OP-3136 showed a clean safety profile with no dose-limiting toxicities or treatment-related discontinuations.</li><li>Side effects were mostly mild to moderate, with tolerability maintained even at higher dose levels across the study population.</li></ul><p>Shares of Olema Pharmaceuticals (OLMA) rose in pre-market trading on Friday after the company reported preliminary Phase 1 clinical data for OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor.&nbsp;</p><p>OP-3136 is a novel oral drug that selectively inhibits KAT6, an epigenetic target linked to breast and other cancers.</p><h2 class="st-heading-2">Promising Signals In Early Clinical Study</h2><p>Olema Oncology said early Phase 1 results for OP-3136 showed the drug “demonstrated acceptable tolerability and promising anti-tumor activity as a monotherapy” across multiple dose levels in advanced solid tumors.</p><p>Sean P. Bohen, president and CEO of Olema Oncology, said shrinkage in tumor size was “observed in over two-thirds of evaluable patients,” along with evidence of target engagement. He added that these findings support continued development of OP-3136, “particularly in combination with palazestrant in metastatic breast cancer.”</p><p>The Phase 1 study is testing OP-3136 through dose escalation and expansion in patients with advanced ER+/HER2- breast cancer, metastatic prostate cancer, and non-small cell lung cancer.&nbsp;</p><p>The drug is being given once daily in 28-day cycles across doses ranging from two mg to 45 mg. As of the March 2026 data cut-off, 32 heavily pretreated patients who had stopped responding to standard treatments were enrolled.</p><h2 class="st-heading-2">Safety, Tolerability, Efficacy</h2><p>OP-3136 was generally well tolerated, with no dose-limiting toxicities observed across the evaluated daily dose range up to 45 mg per day orally. Most side effects were mild to moderate, and no treatment discontinuations were reported due to adverse events. The most common side effects included taste changes, anemia, and neutropenia.</p><p>Among evaluable patients, tumor shrinkage was seen in 13 out of 19. Many patients remain on treatment. The longest treatment duration was 62 weeks.</p><p>OP-3136 showed predictable, dose-related exposure in the body. At doses of 6 mg or higher, drug levels met or exceeded the efficacy targets.</p><p>The data will be presented on May 30 at the ASCO Annual Meeting in Chicago.</p><h2 class="st-heading-2">What Retail Thinks About OLMA Stock</h2><p>On Stocktwits, retail sentiment turned “extremely bullish” from “bearish” a day ago. Message volume also turned “extremely high” from “normal” the previous day.</p><p>Since the start of the year, OLMA shares have dropped by around 46%, but in the past 12 months, it has surged 205%.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday.

Shares of Olema Pharmaceuticals rose in pre-market trading on Friday after the company reported preliminary Phase 1 clinical data for OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. 

Current Price	$7.26
Prev Close	$7.07
Open	$7.12
Dividend Yield	0.00%
50-Day Moving Average	$8.77
Beta	1.07
Avg. Volume	1.32M
PE Ratio	-3.34

52-Week High	$36.26
52-Week Low	$6.24
Market Capitalization	$618.61M
EPS (Annual)	-$1.87
Price to Book	1.44
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

OLMA Fundamentals